171 Oyster Point Boulevard
South San Francisco
About Surrozen, Inc.
Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
The Wnt pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes. Abnormalities in the Wnt pathway have been linked to many human diseases, revealing a powerful underlying biology with relevance to a broad spectrum of organs and tissues. Surrozen is implementing a platform of “surrogate” Wnt molecules to selectively activate the Wnt pathway for the treatment of injury and disease—overcoming key hurdles that have held back industry-wide drug development efforts in this promising area of biology.
Founders: K. Christopher Garcia, Ph.D., Roeland Nusse, Ph.D., Calvin Kuo, M.D., Ph.D. and Claudia Janda, Ph.D.
CEO: Tim Kutzkey, Ph.D.
CSO: Wen-Chen Yeh, M.D., Ph.D.
Senior Director and Head of Discovery Biology: Yang Li, Ph.D.
3 articles with Surrozen, Inc.
1/24/2018Headquartered in South San Francisco, Surrozen focuses on developing drugs by leveraging insights into the Wnt signaling pathway.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.